2024
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease
McDowall S, Bagda V, Hodgetts S, Mastaglia F, Li D. Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease. Translational Neurodegeneration 2024, 13: 59. PMID: 39627843, PMCID: PMC11613593, DOI: 10.1186/s40035-024-00450-9.Peer-Reviewed Original ResearchConceptsPolypyrimidine tract-binding protein 1Expression of polypyrimidine tract-binding protein 1Stem cell transplantationReprogramming of astrocytesCentral nervous system disordersAlzheimer's diseaseNeurodegenerative disordersNervous system disordersCell transplantationReprogram astrocytesTherapeutic strategiesAnimal modelsSystem disordersDisease outcomeRegenerative therapeuticsNeuronal populationsGlial cellsTherapeutic potentialProtein 1NeuronsAstrocyte heterogeneityDiseaseAstrocytesDisordersPublished studies156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataO-083 A METABOLOME-WIDE ASSOCIATION STUDY OF OCCUPATIONAL EXPOSURE TO FORMALDEHYDE
Rothman N, Lin X, Vermeulen R, Zhang L, Pinto-Pacheco B, Tang X, Hu W, Jones D, Guo W, Wen C, Huang Y, Reiss B, Guangdong L, Rappaport S, Smith M, Lan Q, Walker D. O-083 A METABOLOME-WIDE ASSOCIATION STUDY OF OCCUPATIONAL EXPOSURE TO FORMALDEHYDE. Occupational Medicine 2024, 74: 0-0. DOI: 10.1093/occmed/kqae023.0604.Peer-Reviewed Original ResearchEffects of exposure to FAFA exposureImmune system disordersSystemic metabolic processesAssociated with alterationsUntargeted liquid chromatographyPlasma metabolomeMetabolic pathway enrichment analysisNasopharyngeal cancerProstaglandin metabolismOccupational exposure to formaldehydeSystem disordersHuman studiesFatty acid uptakeOccupational exposureArachidonic acidCell proliferationExposure to FAOxidative stressCarnitine shuttleAcid uptakeMitochondrial dysfunctionBiological effectsExposure to formaldehydeAssociation studies
2022
Returning to basic principles to develop more effective treatments for central nervous system disorders
Wexler BE. Returning to basic principles to develop more effective treatments for central nervous system disorders. Experimental Biology And Medicine 2022, 247: 856-867. PMID: 35172621, PMCID: PMC9158240, DOI: 10.1177/15353702221078291.Peer-Reviewed Original ResearchConceptsCentral nervous systemPositron emission tomographyNeuroplastic processesMagnetic stimulationCentral nervous system disordersFunctional magnetic resonance imaging (fMRI) imagingNervous system disordersMagnetic resonance imaging (MRI) imagingSystem-based initiativesCNS diseasesClinical trialsEffective treatmentSystem disordersSide effectsNervous systemNew treatmentsClinical disordersCandidate drugsEmission tomographyBrain functionPreclinical research
2021
Pragmatic Approach to Neuraxial Anesthesia in Obstetric Patients With Disorders of the Vertebral Column, Spinal Cord, and Neuromuscular System
Walsh E, Zhang Y, Madden H, Lehrich J, Leffert L. Pragmatic Approach to Neuraxial Anesthesia in Obstetric Patients With Disorders of the Vertebral Column, Spinal Cord, and Neuromuscular System. Obstetric Anesthesia Digest 2021, 41: 164-165. DOI: 10.1097/01.aoa.0000796068.53863.3d.Peer-Reviewed Original Research
2020
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozinSex effects across the lifespan in women with multiple sclerosis
Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R, Cavalla P, Clerico M, Corona T, Doshi A, Fragoso Y, Jacobs D, Jokubaitis V, Landi D, Llamosa G, Longbrake EE, Maillart E, Marta M, Midaglia L, Shah S, Tintore M, van der Walt A, Voskuhl R, Wang Y, Zabad RK, Zeydan B, Houtchens M, Hellwig K. Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances In Neurological Disorders 2020, 13: 1756286420936166. PMID: 32655689, PMCID: PMC7331774, DOI: 10.1177/1756286420936166.Peer-Reviewed Original ResearchMultiple sclerosisCentral nervous system disordersMS disease activityLong-term prognosisEffect of pregnancyNervous system disordersMS careMS relapsesDisability progressionDisease activityMS riskOvarian agingRelapse riskReproductive yearsSexual dysfunctionDMT useSex effectsMS susceptibilitySystem disordersPregnancyReproductive agingEffects of sexFamily planningWomenMale sex ratio
2018
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Kumar N, Pizzo M, Nehra G, Wilken-Resman B, Boroumand S, Thorne R. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry 2018, 29: 3937-3966. PMID: 30265523, PMCID: PMC7234797, DOI: 10.1021/acs.bioconjchem.8b00548.Peer-Reviewed Original ResearchConceptsCentral nervous systemCNS disordersBlood-cerebrospinal fluid barrierTreatment of CNS disordersCentral nervous system disordersPotential treatment strategyTreating CNS disordersPassive immunotherapy approachesBlood-brain barrierImmunotherapy approachesNervous system disordersDrug deliveryPassive immunotherapyTreatment strategiesSystemic circulationFluid barrierTarget antigenSystem disordersDisease-SpecificNervous systemExogenous antibodiesBrain cancerAntibodiesTherapeutic antibody fragmentsDisease
2017
Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates
Li S, Cai Z, Zheng MQ, Holden D, Naganawa M, Lin SF, Ropchan J, Labaree D, Kapinos M, Lara-Jaime T, Navarro A, Huang Y. Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates. Journal Of Nuclear Medicine 2017, 59: 140-146. PMID: 28747521, PMCID: PMC5750518, DOI: 10.2967/jnumed.117.195586.Peer-Reviewed Original ResearchConceptsPET radiotracersNonhuman primatesTime-activity curvesHigh specific binding signalsΚ-opioid receptor antagonistCentral nervous system disordersFast tissue kineticsBrain time-activity curvesCaudate/putamenNervous system disordersΚ-opioid receptorsRegional binding potentialPeak uptake timeRegional distribution volumesAntagonist radiotracersReceptor antagonistFrontal cortexNovel 18FRegional time-activity curvesSystem disordersNovel radioligandPET scansSpecific binding signalsTemporal cortexMonkey brain
2016
A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration of small-diameter axons associated with intracellular Ca2+ dysregulation and decrease in ATP levels
Rolyan H, Liu S, Hoeijmakers JG, Faber CG, Merkies IS, Lauria G, Black JA, Waxman SG. A painful neuropathy-associated Nav1.7 mutant leads to time-dependent degeneration of small-diameter axons associated with intracellular Ca2+ dysregulation and decrease in ATP levels. Molecular Pain 2016, 12: 1744806916674472. PMID: 27821467, PMCID: PMC5102167, DOI: 10.1177/1744806916674472.Peer-Reviewed Original ResearchConceptsSmall fiber neuropathySmall-diameter axonsTime-dependent degenerationDorsal root ganglion neuronsNerve fiber injuryNervous system disordersPrevious clinical reportsIntracellular calcium levelsMutant Nav1.7 channelsATP levelsAδ nerve fibersHigh altitude sicknessPainful neuropathyTime-dependent increaseFiber injuryClinical onsetGanglion neuronsOxygen species productionSystem disordersCalcium levelsClinical reportsDistal extremitiesIntracellular Ca2NeuropathyNav1.7 channels
2013
Cell Assays: Surface‐Micromachined Microfiltration Membranes for Efficient Isolation and Functional Immunophenotyping of Subpopulations of Immune Cells (Adv. Healthcare Mater. 7/2013)
Chen W, Huang N, Oh B, Lam R, Fan R, Cornell T, Shanley T, Kurabayashi K, Fu J. Cell Assays: Surface‐Micromachined Microfiltration Membranes for Efficient Isolation and Functional Immunophenotyping of Subpopulations of Immune Cells (Adv. Healthcare Mater. 7/2013). Advanced Healthcare Materials 2013, 2: 921-921. DOI: 10.1002/adhm.201370035.Peer-Reviewed Original ResearchEpigenetic Therapies in Neurological Diseases
Huang H, Philpot B, Jiang Y. Epigenetic Therapies in Neurological Diseases. Epigenetics And Human Health 2013, 167-193. DOI: 10.1007/978-3-642-36827-1_8.Peer-Reviewed Original ResearchCentral nervous system disordersNervous system disordersCentral nervous systemHuman clinical trialsEpigenetic therapyPeripheral disordersClinical trialsHistone deacetylation inhibitorsSystem disordersTherapeutic strategiesPsychiatric disordersNervous systemUS FoodDrug AdministrationNeurological diseasesTherapeutic interventionsDisease pathophysiologyClinical useTherapyDisordersDeacetylation inhibitorsSuitable targetEpigenetic abnormalitiesEpigenetic modifiersCurrent understanding
2009
Long‐Term Multilayer Adherent Network (MAN) Expansion, Maintenance, and Characterization, Chemical and Genetic Manipulation, and Transplantation of Human Fetal Forebrain Neural Stem Cells
Wakeman DR, Hofmann MR, Redmond DE, Teng YD, Snyder EY. Long‐Term Multilayer Adherent Network (MAN) Expansion, Maintenance, and Characterization, Chemical and Genetic Manipulation, and Transplantation of Human Fetal Forebrain Neural Stem Cells. Current Protocols In Stem Cell Biology 2009, 9: 2d.3.1-2d.3.77. PMID: 19455542, DOI: 10.1002/9780470151808.sc02d03s9.Peer-Reviewed Original ResearchConceptsCentral nervous system disordersNSC/NPCsNeural stem/precursor cellsNeural stem/progenitor cellsNervous system disordersEarly human neurogenesisStem/precursor cellsSmall molecule drug screeningStem/progenitor cellsForebrain neural stem cellsNeural stem cellsHuman neural stem/precursor cellsAdult rodentsTherapeutic modalitiesParkinson's diseaseSystem disordersCadaveric sourcesMonkey brainAlzheimer's diseaseNeurodegenerative disordersHuman neurogenesisNeuronal migrationDiseaseLong-term maintenanceMigratory capability
2007
Adult-Onset Asthma and Periocular Xanthogranulomas in a Patient With Lymphoplasmacytic Sclerosing Pancreatitis
Roggin K, Rudloff U, Klimstra D, Russell L, Blumgart L. Adult-Onset Asthma and Periocular Xanthogranulomas in a Patient With Lymphoplasmacytic Sclerosing Pancreatitis. Pancreas 2007, 34: 157-160. PMID: 17198199, DOI: 10.1097/01.mpa.0000236737.84982.45.Peer-Reviewed Original ResearchConceptsAdult-onset asthmaLymphoplasmacytic sclerosing pancreatitisPeriocular xanthogranulomaSclerosing pancreatitisRare systemic autoimmune disorderAssociated with autoimmune pancreatitisSpectrum of clinical manifestationsSystemic autoimmune disorderOcular manifestationsInflammatory pseudotumorAutoimmune pancreatitisMultiorgan involvementAutoimmune disordersCase reportClinical manifestationsClinical associationsClinical syndromePancreatitisSystem disordersXanthogranulomaAsthmaPatientsManifestationsDisordersPseudotumor
2006
Topiramate for the treatment of epilepsy and other nervous system disorders
van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Review Of Neurotherapeutics 2006, 6: 19-31. PMID: 16466308, DOI: 10.1586/14737175.6.1.19.Peer-Reviewed Original ResearchConceptsPossible neuroprotective agentsTroublesome adverse effectsOral hypoglycemic agentsCognitive side effectsTreatment of epilepsyNervous system disordersNeuropathic painMigraine prophylaxisNeuroprotective agentsHypoglycemic agentsSystem disordersSide effectsBroad-spectrum efficacyBipolar disorderLow dosesPsychiatric conditionsTopiramateSubstance dependenceAdverse effectsEpilepsyDisordersEfficacySpectrum efficacyMonotherapyProphylaxis
2005
Synthesis and receptor assay of aromatic–ethynyl–aromatic derivatives with potent mGluR5 antagonist activity
Alagille D, Baldwin R, Roth B, Wroblewski J, Grajkowska E, Tamagnan G. Synthesis and receptor assay of aromatic–ethynyl–aromatic derivatives with potent mGluR5 antagonist activity. Bioorganic & Medicinal Chemistry 2005, 13: 197-209. PMID: 15582465, DOI: 10.1016/j.bmc.2004.09.042.Peer-Reviewed Original ResearchConceptsNoncompetitive antagonistMetabotropic glutamate receptor subtype 5Potent mGluR5 antagonistNervous system disordersMGluR5 antagonistSubtype 5Novel noncompetitive antagonistSystem disordersAntagonist activityAntagonistPotential therapeuticsDrug addictionSAR studiesInactive productsCritical roleMGluR5MPEPPain19 Molecular Mechanisms of Calcium Influx in Axonal Degeneration
Stys P, Waxman S. 19 Molecular Mechanisms of Calcium Influx in Axonal Degeneration. 2005, 275-292. DOI: 10.1016/b978-012738761-1/50020-1.Peer-Reviewed Original ResearchExperimental autoimmune encephalomyelitisAxonal degenerationMultiple sclerosisAxonal injuryCalcium influxInflammatory central nervous system disordersCentral nervous system disordersAcute axonal injuryPotential neuroprotective strategiesWhite matter injuryCellular calcium overloadNervous system disordersAutoimmune encephalomyelitisAxonal damageNeuroprotective strategiesGlutamate releasePathophysiological mechanismsCa overloadCalcium overloadSystem disordersInadequate deliveryMyelinated axonsAberrant operationNitric oxideCa channels
2002
Diagnoses Received by Narcolepsy Patients in the Year Prior to Diagnosis by a Sleep Specialist
Kryger M, Walld R, Manfreda J. Diagnoses Received by Narcolepsy Patients in the Year Prior to Diagnosis by a Sleep Specialist. Sleep 2002, 25: 36-41. PMID: 11833859, DOI: 10.1093/sleep/25.1.36.Peer-Reviewed Original ResearchConceptsOnset of symptomsSleep disorders centerCorrect diagnosisNarcolepsy patientsDisorders CenterManitoba Health databaseDiagnosis of narcolepsyNervous system disordersLonger intervalsClinical featuresExcessive daytimeNarcolepsy diagnosisNeurologic conditionsControl subjectsHypnagogic hallucinationsGeneral practitionersNeurologic disordersTeaching hospitalDoctor visitsNocturnal sleepSevere symptomatologySystem disordersGeneral populationSleep specialistsSpecialist evaluation
1988
Schizophrenia: Instability in Norepinephrine, Serotonin, and γ-Aminobutyric Acid Systems
Gelernter J, van Kammen D. Schizophrenia: Instability in Norepinephrine, Serotonin, and γ-Aminobutyric Acid Systems. International Review Of Neurobiology 1988, 29: 309-347. PMID: 3042667, DOI: 10.1016/s0074-7742(08)60091-4.Peer-Reviewed Original ResearchConceptsGABA systemΓ-aminobutyric acid (GABA) systemPathophysiology of schizophreniaClinical instabilitySymptomatic periodClinical syndromeDA dysregulationNeurotransmitter systemsSystem disordersState-dependent changesClinical pathologyConflicting dataSchizophrenia researchSchizophreniaDopamineGenetic vulnerabilitySchizophrenic individualsMost evidenceNorepinephrineSerotoninNE systemDisordersEvidenceRelapsePathophysiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply